Doripenem monohydrate CAS: 364622-82-2

CAS NO: 364622-82-2
Doripenem monohydrate
Chemical Name: Doripenem hydrate
Molecular Formula: C15H26N4O7S2
Formula Weight: 438.51
CAS No.: 364622-82-2
Description Review
Description

Doripenem monohydrate is a broad-spectrum carbapenem antibiotic that is used to treat a variety of bacterial infections, including complicated intra-abdominal infections and complicated urinary tract infections. It was developed by Shionogi & Co. Ltd. The chemical name of doripenem monohydrate is (4R,5S,6S)-3-[[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid monohydrate, and its molecular formula is C15H24N4O6S·H2O. The product has a formula weight of 428.46 g/mol and a CAS No of 364622-82-2.

Top Ten Keywords and Synonyms:

  1. Doripenem mechanism
  2. Doripenem dosage
  3. Doripenem safety
  4. Doripenem side effects
  5. Doripenem benefits
  6. Carbapenem antibiotic
  7. Shionogi drug
  8. Bacterial infections
  9. Urinary tract infections
  10. Intra-abdominal infections

Health Benefits: Doripenem monohydrate has potential benefits in the treatment of bacterial infections, specifically those caused by gram-negative bacteria such as Escherichia coli and Klebsiella pneumoniae. It has been shown to be effective in treating complicated urinary tract infections and complicated intra-abdominal infections. In clinical trials, doripenem monohydrate demonstrated high rates of microbiological eradication and clinical cure.

Potential Effects: The primary effect of doripenem monohydrate is the inhibition of bacterial cell wall synthesis, which ultimately leads to bacterial cell death. It has broad-spectrum activity against gram-positive and gram-negative bacteria, including those that are resistant to other antibiotics. In clinical trials, doripenem monohydrate has demonstrated efficacy in treating complicated urinary tract infections and complicated intra-abdominal infections.

Product Mechanism: Doripenem monohydrate is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to and inhibiting penicillin-binding proteins (PBPs). This leads to the disruption of peptidoglycan cross-linking and ultimately bacterial cell death. Doripenem monohydrate also has broad-spectrum activity against gram-positive and gram-negative bacteria, including those that are resistant to other antibiotics.

Safety: In clinical trials, doripenem monohydrate has been generally well-tolerated by patients, with no reported serious adverse events. However, like all drugs, there are potential risks associated with its use. Patients with a history of hypersensitivity to beta-lactam antibiotics, as well as those with renal impairment, should consult with their healthcare provider before using doripenem monohydrate.

Side Effects: The most common side effects reported in clinical trials were diarrhea, nausea, and headache. These side effects were generally mild to moderate in severity and resolved without intervention. Other less common side effects included allergic reactions, rash, and liver enzyme abnormalities.

Dosing Information: The recommended dose of doripenem monohydrate varies depending on the type of infection being treated and the patient's age and weight. In clinical trials for complicated urinary tract infections and complicated intra-abdominal infections, the typical dose was 500 mg every eight hours, administered intravenously over one hour. Dosing adjustments may be necessary in patients with renal impairment. It is important to follow your healthcare provider's instructions regarding dosing and administration of doripenem monohydrate.

Conclusion: Doripenem monohydrate is a promising antibiotic for the treatment of bacterial infections, specifically those caused by gram-negative bacteria. Its inhibition of bacterial cell wall synthesis leads to bacterial cell death, making it effective against a broad range of bacterial strains. While doripenem monohydrate has been generally well-tolerated in clinical trials, patients should consult with their healthcare provider before using this medication. With further research, doripenem monohydrate may prove to be a valuable addition to the treatment options available for bacterial infections

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code
Message Us